Study guide

9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance

BCSCP Board Certified Sterile Compounding Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, USP Standards & CSP Categories

1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions

2 Chapter 2: Facilities, Engineering Controls & Cleaning

2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures

3 Chapter 3: Environmental Monitoring & Facility Certification

3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols

4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique

4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity

5 Chapter 5: Beyond-Use Dating, Storage & Container Rules

5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules

6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding

6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)

7 Chapter 7: Materials, Equipment & Compounding Workflow

7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs

8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility

8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics

9 Chapter 9: Therapeutics, Administration & Patient Monitoring

9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations

10 Chapter 10: Quality Management, Records & Personnel Competency

10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence

11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain

11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA

12 Chapter 12: Safety Management, Investigations, Recalls & Waste

12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management

9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance

Key Takeaways Explain This Topic AI

Therapeutic drug monitoring for parenteral antimicrobials integrates pharmacokinetic/pharmacodynamic (PK/PD) indices: vancomycin mandates an AUC 24 / MIC \text{AUC}_{24}/\text{MIC} AUC 24 ​ / MIC target of 400 − 600 mg ⋅ h/L 400-600\,\text{mg}\cdot\text{h/L} 400 − 600 mg ⋅ h/L to optimize MRSA bactericidal activity while minimizing nephrotoxicity, whereas aminoglycosides rely on concentration-dependent peak-to-MIC ratios ( C max ⁡ / MIC ≥ 8 − 10 C_{\max}/\text{MIC} \ge 8-10 C m a x ​ / MIC ≥ 8 − 10 ) with undetectable troughs ( < 1 μ g/mL < 1\,\mu\text{g/mL} < 1 μ g/mL ).

Catheter-Related Bloodstream Infections (CRBSIs) arise via extraluminal skin migration (predominant in short-term catheters < 14 < 14 < 14 days) or intraluminal hub/infusate contamination (predominant in long-term catheters > 14 > 14 > 14 days), mediated by dense microbial biofilms produced by Staphylococcus epidermidis , Staphylococcus aureus , and Candida species that confer up to 1,000-fold antibiotic resistance.

Evidence-based CRBSI prevention bundles enforce maximal sterile barriers during insertion, chlorhexidine gluconate skin antisepsis, "scrub the hub" friction with an alcohol-based antiseptic before every access (commonly 5 to 15 seconds, per protocol and product), and prompt removal of unneeded lines.

Chemical phlebitis risk rises with high osmolarity (PN above about 900 mOsm/L 900\,\text{mOsm/L} 900 mOsm/L needs central access), extremes of pH, and known irritant drugs. Loss of patency is handled by cause: alteplase for thrombus, and 0.1 N hydrochloric acid, sodium bicarbonate or 70% ethanol for specific precipitates.

Last updated: September 2026

9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance

Note

Clinical vigilance in parenteral pharmacotherapy bridges sterile compounding quality with clinical patient management. Pharmacists must integrate pharmacokinetic-pharmacodynamic (PK/PD) modeling to prevent nephrotoxic and ototoxic organ injury, enforce intravascular catheter bundles to eradicate biofilm-mediated bloodstream infections, and monitor physicochemical infusion thresholds to prevent severe post-infusion phlebitis.

Pharmacokinetics and Pharmacodynamics (PK/PD) of Parenteral Therapies

Parenteral antimicrobial optimization depends on aligning dosing strategies with the pathogen's pharmacodynamic killing characteristics.

Primary PK/PD Indices of Antimicrobial Efficacy

Time-Dependent Killing ( f T > MIC fT > \text{MIC} f T > MIC ) :

Drug Classes : Beta-lactams (penicillins, cephalosporins, carbapenems, monobactams).

Mechanism : The rate of bacterial killing plateaus once the free, unbound drug concentration exceeds 4 to 5 × MIC 4\text{ to }5\times\text{MIC} 4 to 5 × MIC . Efficacy is determined by the percentage of the dosing interval during which free drug concentrations exceed the pathogen's minimum inhibitory concentration ( f T > MIC fT > \text{MIC} f T > MIC ). For carbapenems, optimal bactericidal efficacy requires 40 % f T > MIC 40\% fT > \text{MIC} 40% f T > MIC ; penicillins require 50 % 50\% 50% ; cephalosporins require 60 − 70 % 60-70\% 60 − 70% .

Compounding Translation : Maximized through continuous infusions or extended infusions (e.g., piperacillin-tazobactam 3.375 g 3.375\,\text{g} 3.375 g infused over 4 hours every 8 hours, or meropenem 1 − 2 g 1-2\,\text{g} 1 − 2 g infused over 3 hours).

Concentration-Dependent Killing ( C max ⁡ / MIC C_{\max}/\text{MIC} C m a x ​ / MIC ) :

Drug Classes : Aminoglycosides (gentamicin, tobramycin, amikacin), fluoroquinolones, daptomycin.

Mechanism : Higher peak concentrations produce faster and more complete bacterial eradication, coupled with a prolonged Post-Antibiotic Effect (PAE) —persistent suppression of bacterial regrowth following drug clearance. Efficacy correlates with achieving high peak-to-MIC ratios ( C max ⁡ / MIC ≥ 8 − 10 C_{\max}/\text{MIC} \ge 8-10 C m a x ​ / MIC ≥ 8 − 10 ).

Exposure-Dependent Killing ( AUC 24 / MIC \text{AUC}_{24}/\text{MIC} AUC 24 ​ / MIC ) :

Drug Classes : Vancomycin, linezolid, polymyxins, daptomycin.

Mechanism : Clinical efficacy correlates with cumulative 24-hour total drug exposure relative to the organism's MIC.

  • Precision Therapeutic Drug Monitoring: Vancomycin and Aminoglycosides
  • Vancomycin AUC-Guided Precision Dosing

For decades, vancomycin therapeutic drug monitoring relied exclusively on trough concentrations ( 15 − 20 μ g/mL 15-20\,\mu\text{g/mL} 15 − 20 μ g/mL ) as a surrogate for serious MRSA infections (bacteremia, endocarditis, osteomyelitis, hospital-acquired pneumonia).

The Nephrotoxicity Shift : The revised ASHP/IDSA/PIDS/SIDP consensus guidelines no longer recommend trough-only monitoring ( 15 − 20 μ g/mL 15-20\,\mu\text{g/mL} 15 − 20 μ g/mL ) . High sustained troughs lead to severe, dose-dependent acute kidney injury (AKI) through proximal tubular epithelial uptake, lysosomal swelling, and intracellular oxidative stress without providing superior clinical cure rates.

The Modern Target Standard : Target a 24-hour Area Under the Curve to MIC ratio ( AUC 24 / MIC \text{AUC}_{24}/\text{MIC} AUC 24 ​ / MIC ) of 400 to 600 mg ⋅ h/L 400\text{ to }600\,\text{mg}\cdot\text{h/L} 400 to 600 mg ⋅ h/L (assuming a conventional broth microdilution MIC of 1.0 mg/L 1.0\,\text{mg/L} 1.0 mg/L ):

AUC 24 / MIC < 400 mg ⋅ h/L \text{AUC}_{24}/\text{MIC} < 400\,\text{mg}\cdot\text{h/L} AUC 24 ​ / MIC < 400 mg ⋅ h/L : Predicts clinical failure and development of vancomycin-intermediate Staphylococcus aureus (VISA).

AUC 24 / MIC > 600 mg ⋅ h/L \text{AUC}_{24}/\text{MIC} > 600\,\text{mg}\cdot\text{h/L} AUC 24 ​ / MIC > 600 mg ⋅ h/L : Significant exponential rise in acute nephrotoxicity.

Monitoring Methods : Calculated using Bayesian software modeling (estimating AUC from a single trough level) or traditional two-point first-order pharmacokinetic equations (peak drawn 1-2 hours post-infusion and trough drawn within 30 minutes prior to the next scheduled dose):

k e = ln ⁡ ( C peak ) − ln ⁡ ( C trough ) Δ t k_e = \frac{\ln(C_{\text{peak}}) - \ln(C_{\text{trough}})}{\Delta t} k e ​ = Δ t l n ( C peak ​ ) − l n ( C trough ​ ) ​

V d = Dose t inf ⋅ k e ⋅ ( 1 − e − k e ⋅ t inf ) ( C peak − ( C trough ⋅ e − k e ⋅ t inf ) ) V_d = \frac{\text{Dose}}{t_{\text{inf}} \cdot k_e} \cdot \frac{(1 - e^{-k_e \cdot t_{\text{inf}}})}{(C_{\text{peak}} - (C_{\text{trough}} \cdot e^{-k_e \cdot t_{\text{inf}}}))} V d ​ = t inf ​ ⋅ k e ​ Dose ​ ⋅ ( C peak ​ − ( C trough ​ ⋅ e − k e ​ ⋅ t inf ​ )) ( 1 − e − k e ​ ⋅ t inf ​ ) ​

Aminoglycoside Extended-Interval High-Dose Dosing

Traditional multiple-daily dosing ( 1 − 2 mg/kg 1-2\,\text{mg/kg} 1 − 2 mg/kg Q8H) has been largely replaced by Extended-Interval Dosing ( 5 to 7 mg/kg 5\text{ to }7\,\text{mg/kg} 5 to 7 mg/kg once daily) for gentamicin and tobramycin.

Pharmacodynamic Advantage : A massive single dose achieves a high peak ( C max ⁡ = 16 − 24 μ g/mL C_{\max} = 16-24\,\mu\text{g/mL} C m a x ​ = 16 − 24 μ g/mL ), ensuring C max ⁡ / MIC ≥ 10 C_{\max}/\text{MIC} \ge 10 C m a x ​ / MIC ≥ 10 and optimizing bactericidal kill while prolonging PAE.

Toxicity Mitigation : Aminoglycoside nephrotoxicity occurs via receptor-mediated endocytosis (megalin and cubilin receptors) in renal proximal tubular cells. These receptors are saturable. Once-daily dosing saturates these receptors transiently, and the prolonged drug-free interval allows drug levels to fall below < 1.0 μ g/mL < 1.0\,\mu\text{g/mL} < 1.0 μ g/mL (or undetectable). This clearance washout facilitates cellular efflux, protecting against acute tubular necrosis (ATN) and ototoxic sensory hair cell destruction in the inner ear.

Catheter-Related Bloodstream Infections (CRBSI): Molecular Pathogenesis

A Catheter-Related Bloodstream Infection (CRBSI) is a primary bloodstream infection originating from an intravascular catheter, verified by differential time to positivity (DTTP: blood culture drawn from the catheter hub turns positive at least 2 hours earlier than a simultaneous peripheral percutaneous blood culture) or quantitative catheter tip segment culture ( ≥ 15 CFU \ge 15\,\text{CFU} ≥ 15 CFU by Maki roll-plate technique). [Intravascular Catheter Ingress Pathways]

  • │
  • ┌───────────────────────────┴───────────────────────────┐
  • ▼ ▼
  • [EXTRALUMINAL PATHWAY] [INTRALUMINAL PATHWAY]
  • ├── Skin microflora at puncture site ├── Contamination of catheter hub,
  • ├── Tracks along outer surface of catheter │ needleless ports, or infusate
  • └── Dominates SHORT-TERM lines (< 14 days) └── Dominates LONG-TERM lines (> 14 days)
  • │
  • ▼
  • [MICROBIAL BIOFILM FORMATION]
  • ├── Primary: S. epidermidis, S. aureus, Candida
  • ├── Synthesis of Extracellular Polymeric Substance (EPS)
  • ├── Persister bacterial cells (quiescent metabolism)
  • └── 100x to 1,000x resistance to systemic antibiotics
  • The Dual Mechanisms of Catheter Colonization

Extraluminal Route : Cutaneous bacteria residing at the insertion site track along the exterior surface of the catheter into the venipuncture canal. This mechanism accounts for the vast majority of infections in short-term central venous lines ( < 14 days < 14\,\text{days} < 14 days ) .

Intraluminal Route : Contamination of the catheter hub, needleless injection ports, or infusate during line access by healthcare workers; bacteria migrate down the internal lumen. This mechanism accounts for the majority of infections in long-term central lines ( > 14 days > 14\,\text{days} > 14 days ) , including tunneled catheters (Hickman, Broviac), PICCs, and implanted subcutaneous ports.

Biofilm Molecular Dynamics and Resistance

Within hours of catheter insertion, host plasma proteins (fibrin, fibronectin, vitronectin, laminin) coat the synthetic polymer catheter surfaces, forming a conditioning film. Free-floating planktonic bacteria adhere to this film:

Biofilm Architecture : Staphylococcus epidermidis (coagulase-negative staphylococcus possessing polysaccharide intercellular adhesin [PIA]), Staphylococcus aureus , Enterococcus faecalis , and Candida species ( C. albicans , C. parapsilosis ) proliferate into dense microcolonies. They secrete an insoluble Extracellular Polymeric Substance (EPS) matrix composed of exopolysaccharides, extracellular DNA, amyloid proteins, and lipids.

Phenotypic Tolerance : Deep within the mature biofilm matrix, bacterial cells transition into a dormant, non-dividing "persister" metabolic state. The polyanionic matrix impedes antibiotic diffusion, while the persister state renders the bacteria insensitive to cell-wall active beta-lactams and glycopeptides. Microbes inside biofilms withstand antibiotic concentrations 100 to 1,000 times higher than their planktonic counterparts, rendering systemic antibiotic infusions ineffective without catheter removal or antimicrobial lock therapy.

Evidence-Based CRBSI Prevention Bundles & Lock Therapy

Adherence to standardized, multi-component insertion and maintenance bundles drastically cuts CRBSI rates.

The Central Line Bundle (CDC / SHEA / INS Standards)

Maximal Sterile Barrier Precautions : Full-body sterile patient drape, sterile gown, sterile gloves, surgical cap, and mask during catheter insertion.

Cutaneous Antisepsis : Skin cleansing with > 0.5 % > 0.5\% > 0.5% chlorhexidine gluconate (CHG) in alcohol , using back-and-forth friction (about 30 seconds for common products) and letting it dry completely, per the product label, before puncture. Povidone-iodine needs about 2 minutes to dry.

Active Connector Antisepsis ("Scrub the Hub") : Scrub the needleless connector with 70% alcohol or alcoholic CHG, with friction, for the time set by protocol and product (commonly 5 to 15 seconds), then let it dry before accessing the line. Use of continuous passive disinfection caps containing 70 % 70\% 70% IPA sponges.

Site Selection : Subclavian vein preferred over internal jugular in adults; femoral site strictly avoided due to high microbial colonization and thrombosis rates.

Daily Assessment of Necessity : Mandatory daily clinical review of line necessity with prompt removal of all non-essential catheters.

Antimicrobial Catheter Lock Therapy (ALT)

When long-term central venous lines (e.g., hemodialysis lines or chemotherapy ports) develop intraluminal CRBSI in stable patients, catheter salvage is attempted using Antimicrobial Catheter Lock Therapy (ALT) :

Principle : Supratherapeutic concentrations of antimicrobials ( 100 to 1 , 000 × MIC 100\text{ to }1,000\times\text{MIC} 100 to 1 , 000 × MIC ) usually with an anticoagulant, are instilled to fill the catheter lumen (about 1.5 to 3.0 mL 1.5\text{ to }3.0\,\text{mL} 1.5 to 3.0 mL ) and left to dwell, alongside systemic antibiotics. IDSA advises renewing the lock at least every 48 hours.

Standard Lock Regimens :

Vancomycin Lock : 2 to 5 mg/mL 2\text{ to }5\,\text{mg/mL} 2 to 5 mg/mL , alone or with heparin (IDSA-listed combinations use heparin from 10 up to 5,000 units/mL).

Gentamicin Lock : 1 to 2 mg/mL 1\text{ to }2\,\text{mg/mL} 1 to 2 mg/mL in 0.9 % 0.9\% 0.9% NaCl + + + Heparin.

Ethanol Lock ( 70 % 70\% 70% Ethanol) : Non-specific protein denaturant and lipid solvent; highly effective at eradicating both bacterial and fungal biofilms with zero risk of microbial resistance. Requires strict monitoring for polyurethane catheter structural softening and systemic intoxication if accidentally flushed.

Post-Infusion Phlebitis: Chemical, Mechanical & Infectious Thresholds

Phlebitis is acute inflammation of the venous tunica intima, manifesting as localized erythema, tenderness, induration, and palpable venous cords.

  • Classification of Phlebitis [Post-Infusion Phlebitis]
  • │
  • ┌────────────────────────────┼────────────────────────────┐
  • ▼ ▼ ▼
  • [CHEMICAL PHLEBITIS] [MECHANICAL PHLEBITIS] [INFECTIOUS PHLEBITIS]
  • ├── Osmolarity > 900 mOsm/L ├── Catheter gauge too large ├── Contamination of insertion
  • ├── Extreme pH (< 5 or > 9) │ relative to vein size │ site or catheter cannula
  • └── Irritating medications ├── Motion / pistoning └── Progression to septic
  • (Vancomycin, Amiodarone) └── Joint flexion insertion thrombophlebitis
  • Chemical Phlebitis: Osmolarity and pH Thresholds

The Peripheral Osmolarity Threshold ( 900 mOsm/L 900\,\text{mOsm/L} 900 mOsm/L ) :

Solutions exceeding 900 mOsm/L 900\,\text{mOsm/L} 900 mOsm/L are strictly contraindicated for peripheral administration and mandate a Central Venous Access Device (CVAD) .

Peripheral arm veins (cephalic, basilic) have sluggish blood flow rates ( 10 to 30 mL/min 10\text{ to }30\,\text{mL/min} 10 to 30 mL/min ). Hyperosmolar infusates rapidly draw cellular water out of endothelial cells, precipitating cellular desiccation, endothelial sloughing, basement membrane exposure, and sterile inflammatory thrombosis.

The superior vena cava (SVC) has a massive blood flow rate of approximately 2 , 000 mL/min 2,000\,\text{mL/min} 2 , 000 mL/min , achieving instantaneous hemodilution of hypertonic infusions within seconds.

pH Extremes ( < 5.0 < 5.0 < 5.0 or > 9.0 > 9.0 > 9.0 ) :

Normal blood pH is 7.35 − 7.45 7.35-7.45 7.35 − 7.45 . A pH outside roughly 5 to 9 5\text{ to }9 5 to 9 is a commonly cited marker of phlebitis risk, although INS guidance now weighs a drug's overall irritant or vesicant properties, not pH alone.

Acidic Irritants (pH < 5.0 < 5.0 < 5.0 ): Vancomycin (pH 2.5 − 4.5 2.5-4.5 2.5 − 4.5 ), Amiodarone (pH 3.5 − 4.5 3.5-4.5 3.5 − 4.5 ), Doxycycline, Potassium chloride admixtures.

Alkaline Irritants (pH > 9.0 > 9.0 > 9.0 ): Phenytoin (pH 12.0 12.0 12.0 ), Acyclovir (pH 10.5 − 11.5 10.5-11.5 10.5 − 11.5 ), Ampicillin.

Infusion Nurses Society (INS) Phlebitis Grading Scale

  • Phlebitis Grade Clinical Presentation & Diagnostic Criteria
  • Grade 0 No clinical symptoms; vascular site intact and non-tender
  • Grade 1 Erythema at access site with or without localized pain
  • Grade 2 Pain at access site accompanied by erythema and/or localized edema
  • Grade 3 Pain at access site with erythema, streak formation, and a palpable venous cord

Grade 4 Pain at access site with erythema, streak formation, a palpable venous cord > 1 inch > 1\,\text{inch} > 1 inch ( > 2.54 cm > 2.54\,\text{cm} > 2.54 cm ) in length, and purulent drainage

Loss of Patency: Catheter Occlusion

Loss of patency is one of the adverse events named in the BCSCP outline. The treatment depends on the cause, so identify it first.

Cause Typical clues Usual management

Thrombotic (fibrin sheath, clot) Gradual loss of withdrawal, then infusion; blood in the lumen Alteplase (Cathflo Activase) 2 mg/2 mL into the lumen, or 110% of the lumen volume up to 2 mg for patients under 30 kg; reassess at 30 and 120 minutes; a second dose may be given

Calcium-phosphate or acidic-drug precipitate Occlusion right after PN or incompatible drugs; visible crystals 0.1 N hydrochloric acid instilled per protocol

Alkaline-drug precipitate (for example phenytoin) Occlusion after alkaline drugs Sodium bicarbonate 8.4% (or dilute sodium hydroxide) per protocol

Lipid residue (TNA or lipid emulsions) Slow occlusion in long-term PN lines 70% ethanol, if the catheter material tolerates it

Mechanical (kink, clamp, pinch-off, malposition) Positional flow; sudden occlusion Check external set; imaging for tip position or pinch-off

Prevention comes from pharmacy work. Check compatibility before co-infusion, keep calcium and phosphate within the solubility curve, filter PN (0.22 µm for 2-in-1, 1.2 µm for TNA), and use flushing protocols such as saline, administer, saline.